COR logo

COR
Cencora Inc.

973
Mkt Cap
$50.14B
Volume
966,084.00
52W High
$377.54
52W Low
$244.82
PE Ratio
19.77
COR Fundamentals
Price
$261.90
Prev Close
$257.71
Open
$257.62
50D MA
$313.19
Beta
0.02
Avg. Volume
1.35M
EPS (Annual)
$7.96
P/B
14.76
Rev/Employee
$6.3M
$66,185.92
Loading...
Loading...
News
all
press releases
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating
Cencora (COR) Emerges as a Healthcare Leader with Robust Fundamentals and Strategic Re-Rating...
Yahoo! Finance: News·6h ago
News Placeholder
More News
News Placeholder
Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation COR
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cencora, Inc. (NYSE: COR) resulting from allegations that Cencora may have issued materially misleading business information to the investing public. So...
Business Wire·3d ago
News Placeholder
Wells Fargo Maintains Overweight Rating on Cencora (COR)
Wells Fargo Maintains Overweight Rating on Cencora (COR...
Yahoo! Finance: News·3d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR PR Newswire NEW YORK, May 14, 2026 NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire·4d ago
News Placeholder
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
Zacks·4d ago
News Placeholder
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
Cardinal Health's Pharmaceutical & Specialty segment posts strong Q3 growth, but can specialty momentum continue powering earnings?
Zacks·5d ago
News Placeholder
Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·6d ago
News Placeholder
Securities Fraud Investigation Into Cencora, Inc. (COR) Announced Shareholders Who Lost Money Urged To ContactGlancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cencora, Inc. (Cencora or the Company...
Business Wire·7d ago
News Placeholder
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·7d ago
News Placeholder
Cencora, Inc. (COR) ShareholdersWho Lost Money ContactLaw Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smithannounces an investigation on behalf ofCencora, Inc. (Cencora or the Company) (NYSE:COR) investors concerning the Companys possible violations of federal securities...
Business Wire·7d ago
<
1
2
...
>

Latest COR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.